Arbutus to Present at the 2018 Wedbush PacGrow Healthcare Conference
WARMINSTER, Pa., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia, Arbutus' Chief Scientific Officer, will present a corporate update at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15, 2018 at 2:30 pm ? 3:00 pm ET in New York.
A live webcast of the presentation can be accessed through the Investor section of Arbutus' website at www.arbutusbio.com. A replay of the webcast will be available for 90 days following the live presentation.
About Arbutus Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Mark Murray President and CEO Phone: 604-419-3200 Email: [email protected]
Expomed Eurasia, the most important medical exhibition between Europe and Asia, is ready to house more than a hundred companies, to discover new technological trends and the most innovative products which are going to change deeply the health market....
Nora Pharma, a Canadian pharmaceutical company, has received approval for its first Biosimilar product.
Nora Pharma, a wholly owned division of Sunshine Biopharma, has received approval from Health Canada for the commercialization of NIOPEG® (a...
PRESS RELEASE FOR IMMEDIATE PUBLICATION 19 April 2024 Dr. Sam Barrell CBE appointed as CEO of LifeArc LifeArc is pleased to announce the appointment of Dr. Sam Barrell, CBE, as Chief Executive Officer. Sam's appointment follows an extensive...
MasterControl, a leading provider of quality management and manufacturing execution software for life sciences, announced it has been recognized by the Imapac 2024 Asia-Pacific Biopharma Excellence Awards in the "Best Bioprocessing Supplier:...
Senstar Technologies Corporation , a leading international provider of comprehensive physical, video and access control security products and solutions, announced today that its Annual Report on Form 20-F for the year ended December 31, 2023 has been...
The report titled "Peptide Therapeutics Market by Technology (Hybrid Phase, Liquid Phase, Solid Phase), Drug Class (Adrenocorticotropic Hormone, Calcitonin, Insulin), Route of Administration, Application, End User, Manufacturing Type - Global...
